Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)

Market Cap	4.63B +0.4%
Revenue (ttm)	459.02M +8.7%
Net Income	33.80M -47.6%
EPS	0.08 -45.3%
Shares Out	417.60M
PE Ratio	138.50
Forward PE	n/a
Dividend	0.06 (0.55%)
Ex-Dividend Date	May 26, 2025

Volume	2,221,642
Average Volume	3,666,349
Open	11.04
Previous Close	11.08
Day's Range	10.79 - 11.05
52-Week Range	10.81 - 16.95
Beta	0.61
RSI	35.77
Earnings Date	Jul 31, 2026

About SHE:301211

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw material...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 952
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301211

Financial Performance

In 2025, SHE:301211's revenue was 453.31 million, an increase of 1.67% compared to the previous year's 445.86 million. Earnings were 34.91 million, a decrease of -61.87%.